Stock Market News
Abcam enters license agreement with Roche
Life science research tools supplier Abcam announced on Monday that it has entered into a definitive license agreement with Roche.
The AIM-traded firm said that, under the terms of the agreement, Abcam would obtain the exclusive rights to the product portfolio of Spring Bioscience Corporation in the research use only (RUO) field of use, comprising a total of approximately 760 unique products.
Roche, which acquired Spring in 2007, would retain the antibody development capabilities and rights pertaining to the Spring portfolio for internal research, companion diagnostic and IVD uses.
Abcam said the core portfolio consisted of 243 recombinant rabbit monoclonal antibodies, branded Spring Proprietary Clones (SP Clones), which had been optimised for immunohistochemistry.
In addition to the SP Clones, the agreement covered approximately 500 additional products, predominantly other monoclonal and polyclonal antibodies.
All products would be sold under the Abcam brand, inclusive of SP branding, and were expected to be available through Abcam's website from 21 February.
Under the terms of the agreement, Abcam was also granted exclusive research use only rights for all future products developed by Spring that Roche requested to be commercialised in the RUO field of use, for an initial period of 10 years and then extendable on mutually agreeable terms.
Financial terms of the agreement were not disclosed.
"This agreement represents an exciting step in the ongoing collaborative and long-term relationship between Abcam and Roche," said Abcam CEO Alan Hirzel.
"By incorporating the Spring Bioscience antibodies into our portfolio, we will be able to better assist our customers, providing them with more products for their most important targets, faster. Abcam is excited to partner with Spring Bioscience, commonly recognised as a leading manufacturer of IHC antibodies, furthering Abcam's mission to provide customers with the highest quality recombinant antibodies for their research."
The AIM-traded firm said that, under the terms of the agreement, Abcam would obtain the exclusive rights to the product portfolio of Spring Bioscience Corporation in the research use only (RUO) field of use, comprising a total of approximately 760 unique products.
Roche, which acquired Spring in 2007, would retain the antibody development capabilities and rights pertaining to the Spring portfolio for internal research, companion diagnostic and IVD uses.
Abcam said the core portfolio consisted of 243 recombinant rabbit monoclonal antibodies, branded Spring Proprietary Clones (SP Clones), which had been optimised for immunohistochemistry.
In addition to the SP Clones, the agreement covered approximately 500 additional products, predominantly other monoclonal and polyclonal antibodies.
All products would be sold under the Abcam brand, inclusive of SP branding, and were expected to be available through Abcam's website from 21 February.
Under the terms of the agreement, Abcam was also granted exclusive research use only rights for all future products developed by Spring that Roche requested to be commercialised in the RUO field of use, for an initial period of 10 years and then extendable on mutually agreeable terms.
Financial terms of the agreement were not disclosed.
"This agreement represents an exciting step in the ongoing collaborative and long-term relationship between Abcam and Roche," said Abcam CEO Alan Hirzel.
"By incorporating the Spring Bioscience antibodies into our portfolio, we will be able to better assist our customers, providing them with more products for their most important targets, faster. Abcam is excited to partner with Spring Bioscience, commonly recognised as a leading manufacturer of IHC antibodies, furthering Abcam's mission to provide customers with the highest quality recombinant antibodies for their research."
Related share prices |
---|
Abcam (ABC) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price